MoonLake Immunotherapeutics (MLTX) stock
MLTX's Quality Score rose 1 point on Mon, Oct 5, to -5. Made a higher high and a higher low.
Follow MLTX's trial news. Pro members can get an alert when MoonLake Immunotherapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for MLTX, and how long its cash lasts
From MoonLake Immunotherapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into the second half of 2027 (8-K, Feb 23).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Aug 10, 2026)
- At-the-market share sales program (S-3ASR, filed Aug 10, 2026)
Insiders
Chief Scientific Officer Kristian Reich sold 1,100 shares on Jul 27, under a planned sale. 13 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 40% in 3 months, 25% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over two years
4 more things pulling MLTX's score down, for Pro members
What's next
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed +2.4% on average, higher 2 of 4 times.
Mon Nov 9: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
4 more dates ahead for Pro members: conferences
What would turn MLTX's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
MLTX has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1428.6
- MACD (12, 26, 9)Above signal
- 50-day average$14.99
- 200-day average$16.75
- ADX 1438.0
- Support$11.06
- Resistance$13.69
- Bollinger Bands (20, 2)Inside
- Volume1.0x
How MLTX ranks in Biotech
MLTX is #253 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
MEDPOpen for its score
MIRMOpen for its score
MLYSOpen for its score
MNOVOpen for its score
MLTX1/14-5
When does MLTX report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 10, 2026Before open | Before open | -5.6% | -5.1% | -9.8% |
| May 11, 2026Before open | Before open | +6.9% | +10.4% | +2.9% |
| Feb 23, 2026Before open | Before open | -0.0% | -0.5% | -6.7% |
| Nov 5, 2025Before open | Before open | +4.6% | +4.5% | +16.0% |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of MLTX's score, with the points and the reason
- All 14 checks on MLTX and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on MLTX
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.